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Introduction
Angiogenesis, the formation of neovasculature, is important
for tumour growth and metastasis, diabetic retinopathy,
rheumatoid arthritis and atherosclerosis (Folkman, 1995;
Kumar et al., 1996). CD105, a receptor for TGF b 1 and
TGF b 3, is a crucial molecule in vascular development and
angiogenesis. Overexpression of CD105 is found in
neoplastic and regenerating tissues where it is implicated in
promoting angiogenesis (Burrows et al., 1995; Seon and
Kumar, 2001; Takahashi et al., 2001; van de Kerkhof et al.,
1998; Wikstrom et al., 2002; Tanaka et al., 2001). Targeted
disruption of the CD105 gene in mice leads to defective
embryonic angiogenesis and foetal death, which indicates
that it is an absolute requirement for normal vascular
development (Arthur et al., 2000; Bourdeau et al., 1999; Li
et al., 1999). CD105 gene mutations in man are responsible
for hereditary haemorrhagic telangiectasia type 1, an
autosomal dominant disorder characterised by multisystemic
vascular dysplasia and recurrent haemorrhage (Shovlin and
Letarte, 1999). We and others have shown that CD105 forms
complexes with the TGF b receptors I and II and actively
regulates TGF b signalling in human vascular endothelial
cells (ECs) and CD105-transfected cells (Lastres et al., 1996;
Li et al., 2000a; Yamashita et al., 1994). TGF b regulates
cell proliferation, differentiation, extracellular matrix
metabolism, angiogenesis and vascular integrity (Pepper,
1997). CD105 appears to function in these processes by
regulating TGF b signalling.
Hypoxia is a common feature of tumour and ischaemic
tissues (Semenza, 2000). If the cellular oxygen concentration
fails to match the requirements of energy metabolism, a
number of genes are triggered to respond to the hypoxic
environment. Hypoxia-inducible genes promote cell survival
by expediting oxygen delivery to the oxygen-deprived tissues
(e.g. erythropoietin) (Wanner et al., 2000), by increasing
glucose transport (e.g. glucose transporter-1) (Ebert et al.,
1995), by raising the levels of glycolytic enzymes (e.g. lactate
dehydrogenase A) (Kambe et al., 1998) and, most importantly,
by promoting angiogenesis (Marti and Risau, 1999; Yue and
Tomanek, 1999). A number of angiogenic factors, such as
vascular endothelial growth factor (VEGF) (Mukhopadhyay et
al., 1995; Schweiki et al., 1992), angiopoietin-2 (Mandriota et
al., 2000), erythropoietin (Huang et al., 1997) and fibroblast
growth factor (Sakaki et al., 1995) are induced by oxygen-
deprivation to facilitate angiogenesis.
Considering the pro-angiogenic function of CD105, we
speculated that there might be an association between oxygen
deprivation and CD105 gene expression. Should such a
relationship exist, it would not only explain the augmented
expression of CD105 in tumours and ischaemic tissues but
would also have therapeutic implications for many angiogenic
diseases. Furthermore, elucidating the function of CD105
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CD105, a marker of endothelial cells, is abundantly
expressed in tissues undergoing angiogenesis and is a
receptor for transforming growth factor b . The pivotal role
of CD105 in the vascular system was demonstrated by the
severe vascular defects that occur in CD105-knockout mice,
but the exact mechanisms for CD105 regulation of vascular
development have not been fully elucidated. In light of the
function of CD105 and the importance of hypoxia in
neovascularisation, we speculated that CD105 is involved
in hypoxia-initiated angiogenesis. Using tissue-cultured
human microvascular endothelial cells, we have
investigated the effects of hypoxic stress on CD105 gene
expression. Hypoxia induced a significant increase in
membrane-bound and secreted CD105 protein levels.
CD105 mRNA and promoter activity were also markedly
elevated, the latter returning to the basal level after 16
hours of hypoxic stress. Hypoxia induced cell cycle arrest
at the G0/G1 phases and massive cell apoptosis after 24
hours through a reduction in the Bcl-2 to Bax ratio,
downregulation of Bcl-XL and Mcl-1, and upregulation
of caspase-3 and caspase-8. The consequence of CD105
upregulation was revealed using an antisense approach and
a TUNEL assay. Suppression of CD105 increased cell
apoptosis under hypoxic stress in the absence of TGF b 1.
Furthermore, hypoxia and TGFb 1 synergistically induced
apoptosis in the CD105-deficient cells but not in the control
cells. We conclude that hypoxia is a potent stimulus for
CD105 gene expression in vascular endothelial cells, which
in turn attenuates cell apoptosis and thus contributes to
angiogenesis. 
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under hypoxic stress would improve our understanding of the
pathogenesis of several vascular diseases in which CD105 is
implicated.
Materials and Methods
Cell culture 
Human dermal microvascular endothelial cells (HDMECs)
(Clonetics, San Diego, CA) were grown in complete growth medium
composed of MCDB 131, 10 ng/ml epithelial growth factor, 10% (v/v)
foetal calf serum (Invitrogen), 2 mM glutamine plus 100 m g/ml
penicillin and 100 m g/ml streptomycin. For hypoxic exposure,
confluent HDMECs were incubated within a modular incubator
chamber filled with a gas mixture of 0.2% oxygen, 5% carbon dioxide
and 94.8% nitrogen placed in a 37°C incubator. Control cells with the
same confluency were maintained at normoxic conditions (20%
oxygen, 5% carbon dioxide and 75% nitrogen) in the same incubator.
To study cell apoptosis under hypoxic stress, HDMECs in complete
growth medium were cultured in the hypoxic chamber in the presence
or absence of recombinant human TGF b 1 (R&D Systems, Abingdon,
UK) for 24 hours. We used ELISAs that were sensitive for TGF b 1
and TGF b 3 [and can detect as little as 20 pg/ml of TGFb 1 and 100
pg/ml of TGFß3 (Li et al., 2000b)], but we did not detect TGF b 1 or
TGF b 3 in the complete growth medium. However, in order to
eliminate any trace amount of TGFb 1 and TGF b 3 in the medium,
neutralising antibodies to TGF b 1 and TGF b 3 were administered in
parallel experiments. Ten m g/ml of chick anti-TGFb 1 (R&D Systems)
and an equal amount of goat anti-TGF b 3 (R&D Systems) were added
to the cultures in the absence of exogenously added TGF b 1 or TGFb 3
during exposure to hypoxia. This antibody concentration was
sufficient to neutralise the bioactivity of 2,000 pg/ml of TGF b 1 and
250 pg/ml of TGF b 3.
To suppress CD105 expression in HDMECs, an antisense approach
was applied as described previously (Li et al., 2000a). Briefly, the 16-
mer antisense phosphorothioate-modified oligodeoxynucleotide (AS
ODN: 5¢ -ATGCTGTCCACGTGGG-3¢ ) and the scrambled control
ODN with the same base composition (SC ODN: 5¢ -ACTCGTGC-
TACGGTGG-3¢ ) were synthesised (Applied Biosystems, Foster City,
CA). Subconfluent HDMECs grown in 35 mm petri dishes were
transfected with 0.5 nM/ml of AS or SC ODN plus 8 m g/ml of DMRIE-
C (Invitrogen) in serum-free medium. After overnight incubation, the
medium was replenished with complete growth medium, and
incubation was continued for an additional 48 hours in normoxia.
Thereafter the medium was replaced with fresh complete growth
medium, and the cultures were exposed to hypoxia for up to 24 hours.
Analysis of CD105 protein expression 
Cell surface expression of CD105 protein in AS-, SC-treated or
untreated cells was quantified by flow cytometry as described
previously (Li et al., 2000a). Briefly, 105 cells per tube were incubated
with 50 m l (10 m g/ml in PBS) of anti-CD105 mAb E9 or pre-
immunised mouse serum as a negative control antibody (10 m g/ml in
PBS) on ice for 1 hour and washed twice with cold PBS. mAb 44G4
to human CD105 (Gougos and Letarte, 1988) was also employed for
comparison with mAb E9. After incubation with a fluorescein-
labelled F(ab´)2 fragment of rabbit anti-mouse antibody (1/40; DAKO,
Denmark) for 30 minutes on ice, the cells were washed and re-
suspended in 0.3 ml of 2% buffered formalin and analysed on a Becton
Dickinson FACScan flow cytometer. 
For analysis of CD105 protein by immunoblotting, CD105 protein
was extracted from HDMECs by solubilising 1 · 107 cells/ml with a
cocktail buffer [0.2% (v/v) Nonidet P-40 in 0.1 M Tris buffer (pH 7.3),
0.5 M PMSF, 1 mM pepstatin, 0.1 mM leupeptin, 1 mM EDTA] and
resolved on 4-7.5% (w/v) sodium dodecyl sulphate (SDS)-
polyacrylamide gel and electrophoretically transferred onto a PVDF
membrane (Millipore) (Li et al., 2000a). mAb E9 (1:1000; 0.5 m g/ml)
in blocking solution was applied to detect CD105 protein, and filters
were incubated overnight at 4°C. Finally, the blots were incubated
with horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG
(DAKO) for 2 hours at 4°C with shaking. The CD105 protein was
visualised using the enhanced chemiluminescence system (Amersham
Biosciences, UK). As an internal loading control, the blot was stripped
and reprobed using a goat anti- a -actin (Sigma) or mouse anti-CD31
antibody (DAKO) and detected by HRP-conjugated secondary
antibodies. CD105 shed into the medium was detected by a
chemiluminescent ELISA system as described previously (Wang et
al., 1995; Li et al., 2000c).
Analysis of CD105 mRNA by northern blotting
Total RNA from HDMECs was extracted using guanidinium
thiocyanate/phenol/chloroform (Chomczynski and Sacchi, 1987).
RNA samples (15 m g) were denatured and fractionated in 1% (w/v)
agarose/2.8% (v/v) formaldehyde gel and blotted onto nitrocellulose.
The CD105 probe used was a 2.3 kb fragment excised with EcoRI
from the pcEXV-EndoL plasmid (Lastres et al., 1996) and labelled
with 32P by random prime labelling. The blot was hybridised with the
32P-labelled probe and the hybridisation was revealed by a
phosphorimager (Molecular Dynamics), then analysed using Image
Quant software. The blots were rehybridised with 32P-labelled probe
for GAPDH for use as a loading control.
Luciferase reporter gene assay
To determine the level of CD105 promoter activity, plasmid pXP2
harbouring the 2.8 kb (–2450/+350) CD105 promoter (Rius et al.,
1998) and a downstream firefly luciferase gene was used for transient
transfection of HDMECs. Internal normalisation was performed by
cotransfection of the pXP2 plasmid with CMV b gal, a b -galactosidase
expression vector driven by the cytomegalovirus (CMV) promoter.
Transfection of HDMECs was carried out using the liposome-
mediated gene transfer technique. Briefly, cells were seeded at 1 · 105
cells per 35 mm dish and the following day were transfected with 8
m g/ml of DMRIE-C (Invitrogen) plus 1 m g of plasmid CMV b gal
mixed with 2 m g of pXP2 in serum-free medium. Twenty-four hours
after transfection, the cultures were replenished with complete
medium and placed in hypoxic or normoxic conditions for the
designated time periods. Thereafter, the cells were harvested and the
enzymatic activity determined. Luciferase and b -galactosidase
activities were measured on a TD-20/20 Luminometer (Promega, WI)
and a colorimetric plate reader (Labsystems), respectively, using kits
from Promega (UK).
Cell cycle analysis
Cell cycle distribution was evaluated by propidium iodide staining of
nuclei and flow cytometric analysis (Li et al., 1997). 1 · 106 cells were
fixed with 2 ml cold 70% (v/v) ethanol in PBS, immediately mixed
and slowly agitated for 15 minutes at room temperature. After two
washes with PBS, 0.7 ml of 0.2 mg/ml pepsin (Sigma) in 2 M HCl
was added to the pelleted cells for simultaneous proteolysis and DNA
denaturation at 37°C for 30 minutes. The hydrolysis was terminated
by addition of 2 ml of 1 M Tris (pH 10). Cells were washed twice and
incubated in 0.3 ml PBS containing 10 m g/ml propidium iodide for
15 minutes on ice. To determine the proportion of cells in various
phases of the cell cycle, propidium iodide staining of the DNA in
2· 104 nuclei was quantified using a Becton Dickinson FACScan flow
cytometer.
Analysis of apoptosis
The terminal deoxynucleotidyltransferase-mediated dUTP end
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labelling (TUNEL) assay was used to identify cell apoptosis. Cells
were seeded onto chamber slides (Nunc) at a density of 2 · 104 cells
per 0.5 ml per well, grown overnight and subjected to hypoxic or
normoxic conditions. Fragmented DNA staining of apoptotic cells
was carried out using a commercial kit (Roche, Mannheim, Germany).
Briefly, the cells were rinsed twice with pre-warmed PBS followed by
fixation using 4% paraformaldehyde for 1 hour at room temperature.
The fixed cells were permeabilised by incubation with 0.1% Triton X-
100 in 0.1% sodium citrate for 2 minutes. The cells were rinsed again
with PBS and incubated with 50 m l per sample of TUNEL reaction
mixture for 1 hour at 37°C. A negative control was included in each
staining wherein only the labelling solution was added. 
TUNEL staining of cells for FACS analysis was carried out using
the same kit as described above. The cells were fixed with a freshly
prepared paraformaldehyde solution (4% in PBS, pH 7.4) for 1 hour
at room temperature. After one wash with PBS, cells were
permeabilised using 0.1% Triton X-100 in 0.1% sodium citrate for 2
minutes on ice, followed by two washes with PBS. The permeabilised
cells were stained with 50 m l/sample of the TUNEL reaction mixture
containing the enzyme or the labelling solution without the enzyme
as a negative control and incubated for 1 hour at 37°C in a humidified
chamber in the dark. Finally, the cells were washed twice with PBS
and resuspended in 0.5 ml PBS for FACS analysis. For quantification
of anti- and pro-apoptotic proteins, cells were harvested, fixed and
permeabilised as described above. Antibodies to Bcl-2, Bcl-XL, Bax,
Mcl-1, caspase-3 and caspase-8 (BD Biosciences) were incubated
with 5· 105 cells/tube for 1 hour on ice. Pre-immunised rabbit serum
or isotype matched mouse immunoglobulins were used as negative
controls. The FITC-conjugated secondary antibodies (DAKO) were
added and incubated for 30 minutes on ice. Flow cytometric analysis
was carried out on a FACScan. 
Results
Hypoxia upregulates CD105 protein levels
HDMECs collected from normoxic or hypoxic cultures were
stained with mAb E9, which reacts specifically with human
CD105 (Pichuantes et al., 1997), and cell surface CD105
expression was quantified by flow cytometry. CD105 levels
were markedly elevated under hypoxic conditions compared
with normoxic conditions, especially after 16 hours (Fig. 1A).
The geometric mean fluorescence intensity increased from
149.5±13.5 in normoxic conditions to 278.0±19.0 after 16
hours of hypoxic culture, that is, an 86.3% increase in cell
surface CD105. FACS analysis was used to compare the
reactivity of mAbs E9 and 44G4 against human CD105 on the
same HDMECs (Gougos and Letarte, 1988; Pichuantes et al.,
1997). Both mAbs reacted with ~100% of the confluent cells
in normoxic conditions. mAbs 44G4 and E9 bound equally
well to HDMECs, resulting in almost identical results under
hypoxic conditions (data not shown). Next, analysis of total
CD105 present in cellular extracts was carried out by
immunoblotting analysis. Cell extracts were prepared from the
same batch of HDMECs used for flow cytometry analysis and
subjected to electrophoresis under non-reducing conditions,
blotted to PVDF membrane and probed using a mAb against
CD105 and a goat anti-a -actin antibody. In contrast to flow
cytometry analysis, which detects only membrane-bound
antigen, immunoblotting identifies total CD105. As depicted
in Fig. 1B, two specific bands with molecular weights of
approximately 180 and 95 kDa were observed. The 180 kDa
band corresponds to the mature dimeric form of CD105 and
showed a ~threefold greater intensity after 16 hours of hypoxic
culture compared with normoxic controls. The smaller band is
Fig. 1. Hypoxia induces CD105 protein expression. HDMECs were
cultured under hypoxic conditions for up to 24 hours, and CD105
expression was quantified by flow cytometry (A), immunoblotting
(B) and ELISA (C) as described in Materials and Methods.
(A) Hypoxic culture resulted in a maximal cell surface expression of
CD105 at 16 hours (86.3% increase). The data represent five samples
at each time point collected from five separate experiments (*P<0.05
and **P<0.01 compared with 0 hours as analysed by one-way
ANOVA followed by the Duncan test). (B) Cell extracts were
resolved on 4-7.5% SDS-PAGE under non-reducing conditions and
electrophoretically transferred onto membranes. The blot was probed
using mAb E9 and a rabbit anti- a -actin antibody. The maximal
expression (as quantified on a densitometer) of CD105 was seen at
16 hours of hypoxic culture. Similar results were observed when the
blots were reprobed using mAb 44G4 (data not shown). The bar
chart shows the CD105 signal intensity relative to actin, pooled from
three experiments. (C) Conditioned medium was collected, and
soluble CD105 levels were quantified using a chemiluminescence
ELISA system. CD105 levels peaked at 16 hours of hypoxic culture.
The data represent six replicates at each time point pooled from three
separate experiments (*P<0.05 and **P<0.01 compared with 0 hours
as analyzed by one-way ANOVA followed by the Duncan test).
Vertical bars indicate the standard error of the means.
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likely to be a monomer of CD105 (Paquet et al., 2001). Both
the dimer and the monomer forms of CD105 were markedly
increased under hypoxic conditions and were maximal at 16
hours, indicating that hypoxia significantly elevated the levels
of total cellular CD105 protein. When the blots were stripped
and reprobed using mAb 44G4, the same bands were observed,
with similar intensity, confirming that the two mAbs to human
CD105 had almost equal reactivity. 
CD105 levels in the blood of patients with breast cancer and
those with atherosclerosis are elevated and associated with
disease progression. Thus CD105 could be a marker for certain
clinical conditions (Blann et al., 1996; Li et al., 2000c). In the
present study, CD105 levels were quantified in conditioned
medium collected from cells used for protein and mRNA
analysis. The levels of secreted CD105 were increased after 1
hour of oxygen deprivation, peaked at 16 hours in hypoxic
cultures and remained higher than controls at 24 hours (Fig.
1C). However the biological implications of the increase in
CD105 are unknown. The profile of secreted CD105 in the
oxygen-deprived medium was comparable to cell surface
CD105 observed by flow cytometry and total CD105 estimated
by immunoblotting analysis.
Hypoxia upregulates CD105 mRNA levels and promoter
activity
To analyse whether the levels of CD105 transcripts were
also affected by hypoxia, total RNA was fractionated and
hybridised with radiolabelled CD105 and GAPDH cDNAs,
visualised on a phosphorimager and quantified using a
densitometer. Hypoxia elevated CD105 mRNA levels, which
was evident even after 1 hour, compared with normoxic culture
(Fig. 2A). The highest expression of CD105 mRNA (a
~threefold increase) occurred at 3 hours. The relatively weak
signal for CD105 mRNA after 24 hours of hypoxic culture was
considered to reflect hypoxia-induced cell cycle arrest and
apoptosis, which was confirmed by propidium iodide staining
and a TUNEL assay, as described below. These low levels of
CD105 mRNA were concomitant with high expression levels
of CD105 protein (Fig. 1), in agreement with the high stability
of the protein (Paquet et al., 2001). To assess whether the
increased CD105 expression in hypoxic conditions was due to
an increased promoter activity, CD105 promoter activity was
examined using a luciferase reporter assay. CD105 promoter
activity was significantly induced by hypoxia, reaching a
maximal level after 3-6 hours of hypoxic culture (Fig. 2B).
Longer durations of hypoxia (more than 16 hours) led to basal
levels of the promoter activity, probably owing to cell cycle
arrest and apoptosis.
Hypoxia induces cell cycle arrest and apoptosis in
HDMECs
Since persistent hypoxia induces alterations in cell cycle and
apoptosis in certain cell types (Carmeliet et al., 1998), an
analysis of cell cycle and apoptosis was performed in hypoxic
HDMECs. Prolonged exposure to hypoxia (24 hours) led to a
dramatic alteration in cell cycle, that is, more cells arrested at
the G0/G1 phases and fewer cells undergoing DNA synthesis
(S phase). Moreover, DNA fragmentation was observed in a
considerable proportion of cells (approximately 21% of the
total population – blue profile) after 24 hours of hypoxic
culture, implying massive cell apoptosis (Fig. 3A). A TUNEL
assay was carried out in parallel on the same batch of cells to
identify cells with fragmented DNA. Under normoxic
conditions, few apoptotic cells were observed. In contrast, in
cells grown under hypoxic conditions DNA fragmentation
occurred in a time-dependent manner: prolonged exposure to
oxygen deprivation induced substantial cell apoptosis (Fig.
3B). The highest proportion of apoptotic cells was detected
after 24 hours of hypoxic culture, which is consistent with the
data obtained by propidium iodide staining. 
Hypoxia alters expression of pro- and anti-apoptotic
markers
To investigate the mechanisms by which hypoxia induces cell
apoptosis, the protein expression of the known anti-apoptotic
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Fig. 2. Effect of hypoxia on CD105 transcription. (A) Northern blot
analysis. Total RNA was extracted from HDMECs and fractionated
on a 1% denaturing agarose gel. After blotting onto a nitrocellulose
membrane, the fractionated RNA was probed using 32P-labelled
cDNAs for CD105 or GAPDH, visualised on a phosphorimager and
quantified using a densitometer. Maximal expression of CD105
mRNA was observed at 3 hours with a ~threefold increase over
normoxic culture. The bar chart represents CD105 mRNA relative to
GAPDH mRNA signal intensity collected from three experiments.
(B) Hypoxia activates the CD105 promoter. HDMECs (the same
batch of cells as for panel A) co-transfected with plasmid
pXP2/pCD105/luc and CMV b gal were grown under hypoxic
condition for up to 24 hours. Luciferase activity was determined and
normalised to b -galactosidase activity. CD105 promoter activity
peaked between 3 hours and 6 hours of culture (*P<0.05 and
**P<0.01 compared with 0 hours as analysed by one-way ANOVA
followed by the Duncan test). Data represent six replicates at each
time point collected from three separate experiments. Vertical bars
indicate standard error of the means.
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markers Bcl-2, Bcl-XL, Mcl-1 and the pro-apoptotic markers
Bax, caspase-3 and caspase-8 were quantified in cells under
normoxia or hypoxia for 24 hours. As shown in Fig. 4, Bcl-XL
and Mcl-1 were significantly suppressed, Bax and Caspase-3
were markedly raised and caspase-8 slightly raised in hypoxia.
Although Bcl-2 was elevated in hypoxia, the ratio of Bcl-2 to
Bax was lowered from 1.36 in normoxia to 0.79 in hypoxia.
These data suggest that hypoxia induces cell apoptosis through
the downregulation of Bcl-XL and Mcl-1, upregulation of Bax,
caspase-3 and caspase-8 and the lowering of the Bcl-2 to Bax
ratio. 
Suppression of CD105 gene expression using an
antisense approach
To investigate the role of CD105 in HDMECs, CD105 gene
expression was specifically inhibited using an antisense
approach. There have been numerous reports in the literature
using the same experimental approach, and the method of
transfection is mild and well-tolerated. Thus, examining the
effect of hypoxia on the transfected cells is considered to be
appropriate. In comparison with HUVECs, in which CD105
was significantly reduced using 0.25 nM/ml of AS ODN plus
5.6 m g/ml of lipofectACE (Invitrogen) (Li et al., 2000a),
HDMECs were less responsive to such a formulation.
However, the efficacy was improved by using an increased
concentration of AS ODN (0.5 nM/ml) plus 8 m g/ml of
DMRIE-C (Invitrogen). FACS and immunoblotting analysis
revealed a 55-60% reduction in CD105 protein levels in the
AS-ODN-treated cells after 72 hours of incubation in normoxia
and 24 hours exposure to hypoxia, compared with SC-ODN-
treated (0.5 nM/ml plus 8 m g/ml DMRIE-C) or untreated cells
under the same conditions (Fig. 5A,B). To investigate whether
CD105 mRNA was altered by ODN treatment, northern
blotting was carried out. As depicted in Fig. 5C, CD105 mRNA
was decreased by AS but not by the SC ODN, demonstrating
that specific degradation of CD105 mRNA was one of the
mechanisms involved in the antisense effect. The specificity of
the antisense effect was further verified by quantifying the
expression of CD31, vWF, TGF b receptor I and receptor II in
the untreated HDMECs or HDMECs treated with either AS or
SC ODN. As determined by FACS and immunoblotting, these
cell membrane proteins were not affected by the ODN
treatment, whereas CD105 protein was significantly reduced
by the AS ODN (data not shown). The selective inhibition of
CD105 gene expression by the AS ODN can also be seen in
Fig. 5, where CD105 but not CD31 protein (A), CD105 but not
GAPDH mRNA (C) were markedly decreased by the AS ODN. 
Inhibition of CD105 gene expression heightens hypoxia-
induced cell apoptosis
Hypoxia stimulates angiogenesis by upregulating expression of
angiogenic factors but causes apoptosis as well. A balance
between the two forces determines the fate of the cell. To
Fig. 3. Cell cycle analysis and TUNEL staining of
cells cultured under hypoxic conditions. HDMECs
were cultured under hypoxic conditions for 0, 6 or 24
hours as indicated. (A) For cell cycle analysis, DNA
was stained using propidium iodide and analysed by
flow cytometry. Hypoxic culture resulted in an
increased number of cells arrested at the G0/G1
phases and an increased level of DNA fragmentation
(blue profile). (B) TUNEL staining was performed on
the same batch of cells used for cell cycle analysis.
Apple green staining of nuclei corresponds to
apoptotic cells. Hypoxic culture led to an increased
number of apoptotic cells (original magnification:
· 250). All experiments were performed at least three
times and produced similar results.
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Fig. 4. Analysis of anti- and pro-apoptotic proteins under hypoxic
conditions. Cells collected after 24 hours of culture under normoxic
or hypoxic conditions were subjected to immunostaining using
specific antibodies and FACS analysis. The ratio of Bcl-2 to Bax
dropped from 1.36 in normoxia to 0.79 in hypoxia. Data were
expressed as means±s.e.m. pooled from duplicate samples of three
experiments (*P<0.05 and **P<0.01, student’s t-test).
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elucidate whether upregulation of CD105 in HDMECs under
hypoxic stress is of functional importance, we quantified
cell apoptosis of the AS-ODN-treated, SC-ODN-treated or
untreated HDMECs. Exposure of untreated cells to hypoxic
stress for 24 hours elicited a significant cell apoptosis, 48.5%
under hypoxia in contrast to 4.3% under normoxia. Hypoxia
induced a maximal cell apoptosis in the CD105-depressed out
of the three groups of cells cultured in complete growth
medium without exogenously added TGF b 1 or TGF b 3. Thus,
the geometric mean fluorescence intensity was 139.1±13.3 in
untreated, 150.7±9.0 in SC-ODN-treated and 193.1±10.6 in
AS-ODN-treated cells (P<0.05, AS-ODN-treated, compared
with either SC-ODN-treated or untreated cells) (Fig. 6A). The
percentage of apoptotic cells correlates well with the geometric
mean fluorescence intensity, which was 66.5% in CD105-
depressed compared with 48.5% in untreated or 48.2% in SC-
ODN-treated cells (P<0.05) (Fig. 6B). Administration of the
neutralising antibodies to TGF b 1 and TGF b 3 produced no
significant alteration either in the percentage of apoptotic cells
or in their fluorescence intensity, demonstrating that CD105 is
able to act independently of TGF b in preventing cell apoptosis
under hypoxic stress. 
Hypoxia and TGFb 1 synergistically augment cell
apoptosis in CD105-depressed cells
CD105 regulate TGF b 1 signalling in endothelial cells and in
CD105 transfectants (Lastres et al., 1996; Letamendia et al.,
1998; Li et al., 2000a) but how CD105 and TGF b 1 interact
under hypoxic conditions to control cell apoptosis has not been
examined. Therefore we investigated this issue using the AS-
ODN-treated (CD105-deficient) cells, the SC-ODN-treated
and untreated cells. As shown in Fig. 6, TGF b 1 induced a
marginal increase in apoptotic cells in the SC-ODN-treated
and the untreated cells. In contrast, it caused a considerable
increase in apoptotic cells in the CD105-depressed cells.
The fluorescence intensity of CD105-deficient cells was
193.1±10.6 in the absence of TGF b 1, 229.7±10.7 at 0.1 ng/ml
of TGFb 1, and 298.2±11.5 at 10 ng/ml of TGFb 1, in contrast
to 150.7±9.0, 157.9±8.7 and 175.6±10.8, respectively, in
SC-ODN-treated cells (P<0.05 or P<0.01, significant
difference between the two groups at each same concentration
of TGFb 1) (Fig. 6A). This represents 28.1%, 45.5% and 69.8%
increases in fluorescence intensity in the CD105-deficient
cells compared with SC-ODN-treated cells at the same
concentrations of TGF b 1. A higher proportion of apoptotic
cells was observed in the CD105-deficient cells compared with
either the SC-ODN-treated or untreated cells at the same
concentration of TGFb 1 (Fig. 6B). The percentage of apoptotic
cells increased from 48.2±2.6, 51.3±3.0 and 56.9±3.0 in SC-
ODN-treated cells at 0, 0.1 and 10 ng/ml of TGF b 1 to
66.5±2.3, 75.7±2.6 and 87.4±2.5 in the AS-ODN-treated cells
at the same concentrations of TGFb 1 (P<0.05 or P<0.01,
significant difference between the two groups at each same
concentration of TGFb 1). These data demonstrate that CD105
functions as an anti-apoptotic protein in the presence of TGFb 1
under hypoxic stress.
Discussion
Hypoxia is a major stimulus of neovascularisation under many
conditions, including tumour angiogenesis, collateral vessel
formation in ischaemic cardiovascular diseases and
proliferative retinopathy (Semenza, 2000; Marti and Risau,
1999; Richard et al., 1999; Smith et al., 1997). CD105 is
upregulated in all these disease states, although its role in
angiogenesis is not fully understood. In this study we
demonstrate that hypoxia activates the CD105 gene promoter,
augmenting its mRNA transcription and protein translation.
Most importantly, our data reveal that CD105 exerts an anti-
apoptotic effect in endothelial cells under hypoxic stress, either
in the absence or in the presence of TGF b 1. In view of these
observations, it can be speculated that hypoxia-initiated
neovascularisation is mediated, at least in part, through the
stimulation of CD105 expression in ECs. 
The notion that CD105 is associated with angiogenesis
initially came from the observation that a mAb to CD105 reacts
most strongly with the endothelium of tumours but only
weakly or not at all with normal tissues (Wang et al., 1993).
Subsequently, numerous studies using mAbs to CD105 on a
broad range of tissues have provided supportive evidence that
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Fig. 5. CD105 mRNA and protein expression in ODN-treated and
untreated cells. HDMECs were cultured for 72 hours in normoxia in
the presence or absence of ODN plus DMRIE-C, followed by
exposure to hypoxia for 24 hours. CD105 protein levels were
assessed by immunoblotting and FACS, and mRNA levels were
assessed by northern blotting. (A) Immunoblotting revealed that
CD105 protein was reduced by ~58% in AS-ODN-treated cells (lane
2) compared with SC-ODN-treated (lane 3) and untreated cells (lane
1). The bar chart indicates the ratio of CD105 relative to CD31 signal
intensity collected from three experiments (means±s.e.m.). (B) FACS
analysis of cell surface CD105 indicated a ~60% reduction in AS-
ODN-treated (blue profile) compared with SC-ODN-treated (green
profile) or untreated (black profile) cells. The red profile represents a
negative control, where mAb E9 was substituted with pre-immunised
mouse serum. The plot is a representative of five similar experiments.
(C) Northern blotting of CD105 and GAPDH mRNA showed that
CD105 mRNA was markedly degraded by AS ODN (lane 2) but not
by SC ODN (lane 3). Lane 1 is mRNA extracted from untreated
cells, and it has no evident alteration compared with lane 3. The bar
chart shows CD105 mRNA, relative to GAPDH mRNA signal
intensity, pooled from three experiments (means±s.e.m.). 
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CD105 is indeed upregulated in many types of tissues
undergoing angiogenesis (Kumar et al., 1996; Miller et al.,
1999; Seon and Kumar, 2001; Wikstrom et al., 2002). The
expression of CD105 in blood vessels of breast and lung cancer
tissues was found to be correlated with poor prognosis (Kumar
et al., 1999; Tanaka et al., 2001), which suggests that CD105
promotes tumour progression. A conclusive demonstration of
the crucial role of CD105 in vascular development came
from CD105-knockout mice, which had severe defects in
angiogenesis; the homozygotes died in utero owing to impaired
development of vasculature (Arthur et al., 2000; Bourdeau et
al., 1999; Li et al., 1999). In line with these observations,
CD105 expression correlates with activation/proliferation of
tumour endothelial cells (Kumar et al., 1999; Miller et al.,
1999). These findings provide compelling evidence that
CD105 is important for angiogenesis. However, the underlying
mechanism of how CD105 promotes angiogenesis is not clear.
Existing data support the view that CD105 overexpression in
transfectants weakens the effects of TGFb 1 and that these
effects might be cell type dependent (Lastres et al., 1996;
Letamendia et al., 1998). In addition, suppression of CD105 in
ECs with antisense ODN in combination with TGF b 1 led to a
strong inhibition of angiogenesis (Li et al., 2000a). These
observations indicate that CD105 modulates TGF b 1 signalling
in these cells and that an adequate level of CD105 in ECs is
required for angiogenesis. 
The expression of CD105 is likely to be regulated by factors
involved in angiogenesis and/or vessel remodelling. Here we
have demonstrated that CD105 is markedly induced in ECs by
exposure to hypoxia. CD105 promoter activity and mRNA
transcription responded rapidly to hypoxia, which suggests that
it is regulated at the transcriptional level. In this regard, a
consensus hypoxia responsive element (HRE) has been
recently characterized within the CD105 promoter (Sanchez-
Elsner et al., 2002). The CD105 protein was maintained at high
levels until the end of the experiment. The half-life of CD105
on the cell surface has been estimated to be 17 hours, measured
by metabolic labelling (Paquet et al., 2001). Thus, once it is
upregulated, CD105 can remain in the EC, exhibiting a
prolonged effect. The relatively low promoter activity and
mRNA level after 24 hours of hypoxic culture is apparently
a consequence of hypoxia-induced cell cycle arrest and
apoptosis. This is in line with previous observations that
CD105 is more strongly expressed in activated/mitotic cells
than quiescent cells, suggesting that it is a proliferation-
associated gene. These findings also highlight the potential
value of the CD105 promoter for gene therapy in cancer and
ischaemic diseases (Brekken et al., 2002; Velasco et al., 2001).
Genes driven by the CD105 promoter may be more strongly
and specifically expressed in the oxygen-deprived tissues and
exert therapeutic effects. 
Hypoxia is the primary driving force for neovascularisation.
The major angiogenic factors, such as VEGF and bFGF, are
upregulated by hypoxia, and promote angiogenesis and thus
improves oxygen supply to the hypoxic tissues
(Mukhopadhyay et al., 1995; Sakaki et al., 1995; Schweiki et
al., 1992). On the other hand, persistent hypoxic stress induces
EC apoptosis (Carmeliet et al., 1998; Hogg et al., 1999). In this
study we have shown that the pro-apoptotic proteins Bax,
caspase-3 and caspase-8 were elevated and that the anti-
apoptotic proteins Bcl-XL and Mcl-1 were significantly
decreased under hypoxic stress. Although anti-apoptotic Bcl-2
was upregulated, the ratio of Bcl-2 to Bax was considerably
lowered under hypoxic stress compared with normoxia.
Therefore, the mechanisms of hypoxia-induced EC apoptosis
largely depend on the lowered Bcl-2 to Bax ratio, Bcl-XL and
Mcl-1 and increased expression of caspase-3 and caspase-8.
These findings are in agreement with previous reports
(Khurana et al., 2002; Taraseviciene-Stewart et al., 2001; Wang
et al., 2002). 
Because CD105 is strongly expressed in the HDMECs under
hypoxic conditions, we adopted an antisense approach to
suppress CD105 expression so that its function could be
specifically addressed. The CD105 protein and mRNA levels
were considerably reduced by the antisense ODN but not
affected by the control SC ODN. Using the CD105-deficient
cells and the control cells, an important function of CD105 has
been discovered, which is that it acts as an anti-apoptotic
protein in ECs under hypoxic stress. Such an effect was
observed in the absence of TGF b 1 and TGF b 3, indicating that
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Fig. 6. Effect of CD105 antisense ODN on cell apoptosis. Three
groups of cells, AS- or SC-ODN-treated or untreated HDMECs,
were exposed to hypoxia and/or TGF-b 1 for 24 hours, TUNEL-
stained and analysed by FACS. The fluorescence intensity (A) and
percentage of apoptotic cells (B) were determined. The apoptotic
effect of TGF b 1 was observed to be concentration dependent, with
the maximal effect of TGFb 1 at 10 ng/ml. Data were expressed as
means±s.e.m. collected from six samples of three experiments.
(*P<0.05 and **P<0.01, one-way ANOVA followed by the Duncan
test).
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CD105 functions beyond its role as a receptor for TGF b 1 and
TGFb 3. In fact, only approximately 1% of membrane-bound
CD105 binds to TGFb 1 and TGF b 3 (Cheifetz et al., 1992). The
function of the majority of CD105 that does not bind to TGF b
remains unclear. Our data suggest that the non-TGF b -binding
CD105 in EC plays a self-protective role against apoptotic
factors such as hypoxia. The protective role of CD105 against
apoptosis has been further confirmed using a completely
different system – murine endothelial cells from CD105
heterozygous knockout mice (J.M.L.-N., C.L., S.K. et al.,
unpublished). The addition of TGF b 1 to control cells under
hypoxia induced a marginal increase in the proportion of
apoptotic cells, whereas the apoptotic action of TGF b 1
was considerably increased in the CD105-depressed cells,
demonstrating that the upregulation of CD105 protects ECs
from the apoptotic action of TGFb 1. In an in vivo environment,
where both hypoxia and TGFb 1 can co-exist, the augmented
expression of CD105 may act as an anti-apoptotic force, so as
to protect ECs against hypoxia and against TGFb 1-induced
apoptosis. 
In conclusion, we have demonstrated that hypoxia activates
the CD105 promoter and significantly induces its gene
expression in human microvascular ECs. The upregulated
CD105 exhibits a role in self-protection against hypoxia and
TGFb 1-induced cell apoptosis, resulting in an enhanced
survival ability of EC under hypoxic stress. These findings may
lead us to a better understanding of the functions of CD105 in
angiogenesis and of the pathogenesis of other CD105-related
vascular disorders. 
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